What it sells
AI Agents for Pharma Drug Launches
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of Global Market Access / Pricing & Market Access at pharma companies.
Trigger: what makes them buy now?
UnverifiedUpcoming drug launch or pricing decision requiring analog research, HTA outcomes and cross-country price benchmarking that currently takes weeks of manual research.
Workflow: what inputs become what output?
Ask plain-language questions over a database of clinical, regulatory, HTA and pricing data; run analog research, disease landscaping, competitor monitoring, price comparison and launch sequence analysis with every figure traced to source; or commission expert-written reports.
Economics: what it saves and how it charges
Software platform plus expert-led services; value claim is turning weeks of manual research into answers in minutes; 0% churn claimed since launch.
Distribution: how it reaches customers
Demo-led sales (Book a demo) and scoped service projects (Scope your project) to large pharma.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.